Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view).
Regeneron Pharmaceuticals (REGN) is trading at $791.33, down 1.31% on the day. Its market value of $81.47B makes it the 199th largest of the 300 companies we follow.
The 52-week range is $538.24 to $859.34. Today's price is about 79% of the way from the low to the high. Holders are ahead 37.9% over twelve months, and up 27.1% across the last three months.
On the chart it holds above both the 50-day ($771.58) and 200-day ($733.28) moving averages; RSI is 53, and the last 30 sessions moved at roughly 26% annualized volatility.
For the quarter ended Jun 2026 it reported $4.29B in revenue, up 16.7% from a year earlier, with $1.30B of net profit (a 27.9% margin).
Valuation works out to 19.6 times trailing earnings, 8% above its five-year average of 18.1. The median for its industry group is 34.0.
19 analysts follow the stock and the average call is "buy". The mean target, $841.37, sits 6.3% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Regeneron is a biotech company best known for the eye drug Eylea and the inflammation drug Dupixent, developed with Sanofi.
What tends to move it. Dupixent growth, competition from Eylea biosimilars and the oncology pipeline decide the outlook.
Written by hand by the BeStock desk and revised when a business changes. See how we work. Spot something out of date? Tell us.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -1.6% | Bearish |
| Price vs 50-day average | +2.6% | Bullish |
| Price vs 200-day average | +7.9% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 53.5 | Bullish |
| MACD (12,26,9) | 3.33 | Bearish |
| Bollinger band position | 35% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Sep 24, 2026 1:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 300 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A row is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Latest reported quarter: Q2, ended Jun 2026
Quarter 2026/Q2
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Multiples measured against the stock's own five-year history
Above its usual level · 63rd percentile, 5-year average 18.1x
#1514 of 2974 stocks by PE (1 = cheapest)
Below its usual level · 24th percentile, 5-year average 3.3x
#3327 of 5298 stocks by PB (1 = cheapest)
Below its usual level · 38th percentile, 5-year average 5.9x
#3880 of 5139 stocks by PS (1 = cheapest)
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Who holds it, who is betting against it, and where the big money is moving
Net of large-order buying minus selling, in USD. Over this window: −$8.49M (10 inflow days, 10 outflow days).
$791.33 is the latest print for REGN, a move of -1.31% against yesterday's close of $801.82. Today's low and high so far: $789.41 and $807.21.
Equity value comes to $81.47B at the current price. By that measure it is number 199 of the 300 names in our coverage.
Buyers pay 19.6 times the last twelve months of profit (EPS $41.48). Averaged over five years the multiple has been 18.1, and today's level ranks in the 63rd percentile of its own history.
The year's floor is $538.24 and the ceiling $859.34. Shares are 7.9% away from that ceiling.
It does. Payouts over the past twelve months work out to a 0.46% yield; the latest ex-dividend date was August 18, 2026.
Of 19 analysts, 63% say buy, 37% hold and 0% sell. Price targets average $841.37, with the most cautious at $700.00 and the most optimistic at $1,030.00.
Regeneron is a biotech company best known for the eye drug Eylea and the inflammation drug Dupixent, developed with Sanofi.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.